Orthopediatrics Q3 2026 earnings

KIDS · 2026-10-27 16:07 AMC ET · 8-K on SEC

Record revenue and adjusted EBITDA with positive free cash flow, supported by increased full-year guidance.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$72.7M+19%—Ex. 99.1, Income Statement
EPS (GAAP)-$0.25+50%—Ex. 99.1, Income Statement
EPS (adjusted)-$0.25+50%—Ex. 99.1, Income Statement
Net income-$5.9M+50%—Ex. 99.1, Income Statement
Adj. EBITDA$6.9M+11%—Ex. 99.1, Income Statement
Adj. EBITDA margin9.5%+1.2 pp—Ex. 99.1, Income Statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Trauma & Deformity$52.6M+19%72%Driven by Cannulated Screws, PNP Femur, PediPlates, 3P Hip, and OPSB growth
Scoliosis$19.2M+18%26%Driven by VerteGlide and Response
Sports Medicine/Other$0.9M+2%1%—
U.S.$57.9M+19%80%—
International$14.8M+18%20%—

Margins and costs

  • Gross margin 74% (prior 74%, change 0 pp)
  • Operating expenses $58.2M (+6% YoY)
  • One-offs in the quarter Intangible asset impairment $0.6M; Fair value adjustment of contingent consideration $0.8M; Restructuring charges $0.0M; Tariffs $0.2M; European Union Medical Device Regulation fees increase $0.0M; Acquisition-related costs $0.3M; Minimum purchase commitment cost $0.0M
  • Effective tax rate 2% (prior-year 1%, year-to-date 0.2%)
  • Non-GAAP bridge Adds back intangible asset impairment, fair value adjustment of contingent consideration, restructuring charges, tariffs, EU MDR fees increase, acquisition-related costs, and minimum purchase commitment costs.

KPIs

MetricActualPrior quarterPrior yearChange
Free cash flow$1.6M-$3.4M-$3.4M+147% YoY
Weighted average shares outstanding24.15M23.57M23.57M+2.5% YoY

Guidance

MetricGuidePrior guideChange
Full year 2026 revenue$270.0M - $273.0M$265.0M - $269.0M+$5.0M - $4.0M
Full year 2026 set deployment$10.0M$10.0MNo change
Full year 2026 adjusted EBITDA$25.0M$25.0MNo change
Full year 2026 free cash flowBreakevenBreakevenNo change

What drove it

  • Revenue story Total revenue grew 19% YoY to $72.7M, driven by growth in global Trauma & Deformity (19%) and Scoliosis (18%) segments, with both U.S. and international revenue increasing 19% and 18% respectively.
  • EPS story Net loss per share improved to -$0.25 from -$0.50, driven by higher revenue, improved operating margins, and lower tax expense.
  • One-off check Intangible asset impairment $0.6M and fair value adjustment of contingent consideration $0.8M are one-time items.

The good

  • Record revenue of $72.7M (+19% YoY)
  • Record adjusted EBITDA of $6.9M (+11% YoY)
  • Positive free cash flow of $1.6M (+147% YoY)
  • Gross margin maintained at 74%

The bad

  • Net loss of $5.9M
  • Operating expenses increased 6% YoY driven by sales commissions and personnel

The ugly

  • none

Open questions

  • The release mentions 'significant unmet needs' but does not quantify the market opportunity.
  • The press release references a 'strong pipeline of new products' but does not provide specific financial projections for these launches.
  • The release mentions 'clinic expansions and small-scale acquisitions' but does not provide details on the timing or financial impact of these activities.
Full release

Earnings: KIDS — filed 2026-10-27

ORTHOPEDIATRICS CORP (KIDS) · Form 8-K, Item 2.02 · Filed · SEC filing

OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance

Record Third Quarter 2026 Revenue of $72.7 Million, Up 19% Year-over-Year

WARSAW, Ind., October 27, 2026

-- OrthoPediatrics Corp.

(“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 and Recent Business Highlights

• Helped nearly 42,000 children in the third quarter of 2026

• Generated new record high total revenue of $72.7 million for the third quarter of 2026, up 19% from $61.2 million in the third quarter of 2025; domestic revenue increased 19% and international revenue increased 18% in the quarter

• Grew worldwide Trauma & Deformity revenue 19% in the third quarter of 2026 compared to the third quarter of 2025, and grew Scoliosis revenue 18% in the third quarter of 2026 compared to the third quarter of 2025

• Achieved record adjusted EBITDA of $6.9 million in the third quarter of 2026, compared to $6.2 million in the third quarter of 2025

• Generated free cash flow of $1.6 million in the third quarter of 2026, a $5.0 million improvement as compared to $3.4 million of usage in the prior year period

• Announced full market release of 3P™ Pediatric Plating Platform® Hip System, and the PediHip Rigid Brace

• Continued to expand the portfolio with multiple new products, including FDA clearance and subsequent limited launch of PNP Retrograde, the limited launch of OPSB® Knee 'TractorFIX, and the limited launch of 3P™ Pediatric Plating Platform® Small Mini

• Increased full year 2026 revenue guidance to $270.0 million to $273.0 million from its prior range of $265.0 million to $269.0 million, representing growth of 14% to 16% compared to prior year

“In the third quarter, we continued to build on the momentum in our business, gaining share in Trauma and Deformity and Scoliosis globally, and continued substantial progress with our OPSB strategy. This quarter, we not only drove revenue growth, but we continued to improve profitability, and generated positive free cash flow. We remain confident in our ability to continue to drive these metrics forward," said David Bailey, President & CEO of OrthoPediatrics. "Our innovation super cycle is an important part of that opportunity, with a strong pipeline of new products coming over the next several years that are expected to deliver higher value and improved capital efficiency. We believe these launches will be an important driver of our financial performance as we bring new solutions to more surgeons and hospitals. There are still significant unmet needs in pediatric orthopedics, and we believe OrthoPediatrics is well positioned to capitalize on that opportunity. Our focus remains on growing the business, improving our operating performance, and achieving breakeven or better free cash flow on an annual basis in 2026 and beyond while continuing to deliver innovative solutions for children.”

Third Quarter 2026 Financial Results

Total revenue for the third quarter of 2026 was $72.7 million, a 19% increase compared to $61.2 million for the same period last year. U.S. revenue for the third quarter of 2026 was $57.9 million, a 19% increase compared to $48.7 million for the same period last year, representing 80% of total revenue. The increase in revenue in the third quarter of 2026 was driven primarily by growth in global Trauma and Deformity and OPSB products. International revenue for the third quarter of 2026 was $14.8 million, an 18% increase compared to $12.5 million for the same period last year, representing 20% of total revenue. Growth in the quarter was primarily driven by increased procedure volumes.

Trauma and Deformity revenue for the third quarter of 2026 was $52.6 million, a 19% increase compared to $44.1 million for the same period last year. This growth was driven primarily by numerous product lines, specifically our Cannulated Screws, PNP Femur, PediPlates, the addition of 3P Hip, as well as continued OPSB growth. Scoliosis revenue was $19.2 million, an 18% increase compared to $16.3 million for the third quarter of 2025. The increase was due to increased revenue generated from VerteGlide and Response. Sports Medicine/Other revenue for the third quarter of 2026 was $0.9 million, a 2% increase compared to $0.8 million for the same period last year.

Gross profit for the third quarter of 2026 was $54.0 million, a 19% increase compared to $45.3 million for the same period last year. Gross profit margin for the third quarter of 2026 was 74%, consistent with the same period last year.

Total operating expenses for the third quarter of 2026 were $58.2 million, a 6% increase compared to $54.7 million for the same period last year. The increase was mainly driven by increased sales commission expense as well as additional personnel supporting clinic expansions and small-scale acquisitions.

Sales and mark eting expenses increased $4.4 million, or 24%, to $23.1 million in the third quarter of 2026. The increase was driven primarily by increased sales commission expenses and an overall increase in volume of units sold.

Research and development expen ses increased $0.1 million, or 6%, to $2.5 million in the third quarter of 2026. The increase was primarily due to ongoing product development during the third quarter of 2026.

General and administrative expenses increased $2.9 million, or 10%, to $32.0 million in the third quarter of 2026. The increase was primarily due to the additional personnel supporting clinic expansions and small-scale acquisitions.

Intangible asset impairment recorded during the third quarter of

2026... (truncated) reduce the carrying amount of the intangible assets to their estimated fair value.

Total other expense was $1.8 million for the third quarter of 2026, compared to other expense of $2.5 million for the same period last year. The change was primar ily driven by a $0.8 million non-cash fair value adjustment of contingent consideration, additional interest expense in 2026 compared to 2025, as well as changes in foreign exchange gains and losses. Foreign exchange losses were primarily driven by changes in the Euro exchange rate, as the Euro declined in value during the three months ended

September 30, 2026, compared to Euro appreciation for the three months ended September 30, 2025.

Net loss for the third quarter of 2026 was $5.9 million, compared to $11.8 million for the same period last year. Net loss per share for the period was $0.25 per basic and diluted share, compared to $0.50 per basic and diluted share for the same period last year.

Adjusted EBITDA for the third quarter of 2026 was $6.9 million as compared to $6.2 million for the third quarter of 2025.

Weighted average basic and diluted shares outstanding for the three months ended September 30, 2026, was 24,153,621 shares.

As of September 30, 2026, cash, cash equivalents, short-term investments and restricted cash were $44.9 million compared to $62.9 million as of December 31, 2025. Free cash flow generated in the third quarter of 2026 was $1.6 million, a

147% improvement as compared to $3.4 million used in the third quarter of 2025. Increased adjusted EBITDA, lower sets deployed and improved working capital metrics all contributed to the year-over-year improvement.

Full Year 2026 Financial Guidance

For the full year of 2026, the Company is increasing its revenue guidance to $270.0 million to $273.0 million from its prior range of $265.0 million to $269.0 million, representing growth of 14% to 16% over 2025 revenue. The Company reiterated it expects annual set deployment to be approximately $10.0 million, expects adjusted EBITDA of approximately $25.0 million, and expects to achieve breakeven free cash flow in 2026.

Conference Call

OrthoPediatrics will host a conference call on Tuesday, October 27, 2026, at 4:30 p.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available for replay for at least 90 days after the event.

Financial statements

Income Statement

Three Months Ended September 30, — (In Thousands, Except Share and Per Share Data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net revenue72,66161,250202,530174,743
Cost of revenue18,68515,97652,79847,188
Gross profit53,97645,274149,732127,555
Operating expenses:Sales and marketing23,09618,65262,86054,327
Operating expenses:General and administrative32,02929,15595,86689,878
Operating expenses:Intangible asset impairment6112,2686112,268
Operating expenses:Restructuring2,29415,305
Operating expenses:Research and development2,4652,3337,0216,843
Operating expenses:Total operating expenses58,20154,702166,359158,621
Operating expenses:Operating loss-4,225-9,428-16,627-31,066
Other expense (income):Interest expense, net2,6171,8227,2484,064
Other expense (income):Fair value adjustment of contingent consideration-814-814
Other expense (income):Other expense (income), net11648765-5,705
Other expense (income):Total other expense (income), net1,8142,4707,199-1,641
Other expense (income):Net loss before income taxes-6,039-11,898-23,826-29,425
Other expense (income):Income tax (benefit) charge-109-125-46120
Other expense (income):Net loss-5,930-11,773-23,780-29,545
Other expense (income):Weighted average common stock - basic and diluted24,153,62123,565,77923,964,17123,420,158
Other expense (income):Net loss per share – basic and diluted-0.25-0.5-0.99-1.26

Income Statement

Three Months Ended September 30, — (In Thousands) (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net loss-5,930-11,773-23,780-29,545
Interest expense, net2,6171,8227,2484,064
Other expense (income), net11648765-5,705
Income tax charge (benefit)-109-125-46120
Depreciation and amortization5,6215,29917,04815,517
Intangible asset impairment6112,2686112,268
Stock-based compensation4,4194,25112,59213,362
Fair value adjustment of contingent consideration-814-814
Restructuring charges2,29415,305
Tariffs178306570954
European Union Medical Device Regulation fees increase109
Acquisition-related costs3429431,6912,532
Minimum purchase commitment cost261960
Adjusted EBITDA6,9466,19415,8869,941

Balance Sheet

September 30, 2026 — (Unaudited) (In Thousands, Except Share Data)

September 30, 2026 – ASSETSDecember 31, 2025 – ASSETS
Current assets:Cash17,14119,556
Current assets:Restricted cash7102,064
Current assets:Short-term investments27,08841,295
Current assets:Accounts receivable - trade, net of allowances of $1,619 and $1,501, respectively59,54353,838
Current assets:Inventories, net141,864133,790
Current assets:Prepaid expenses and other current assets6,8955,876
Current assets:Total current assets253,241256,419
Current assets:Property and equipment, net46,94149,555
Other assets:Amortizable intangible assets, net61,66864,802
Other assets:Goodwill118,586109,269
Other assets:Other intangible assets12,20012,909
Other assets:Other non-current assets16,45115,676
Other assets:Total other assets208,905202,656
Other assets:Total assets509,087508,630
Current liabilities:Accounts payable - trade24,48518,786
Current liabilities:Accrued compensation and benefits16,65713,693
Current liabilities:Current portion of long-term debt with affiliate174170
Current liabilities:Current portion of acquisition installment payable1,6912,194
Current liabilities:Other current liabilities12,62511,354
Current liabilities:Total current liabilities55,63246,197
Long-term liabilities:Long-term term loan48,56048,189
Long-term liabilities:Long-term convertible note48,96148,486
Long-term liabilities:Long-term debt with affiliate, net of current portion152283
Long-term liabilities:Other long-term debt, net of current portion5152,862
Long-term liabilities:Acquisition installment payable, net of current portion3,0532,898
Long-term liabilities:Deferred income taxes3,1403,582
Long-term liabilities:Other long-term liabilities9,7249,537
Long-term liabilities:Total long-term liabilities114,105115,837
Long-term liabilities:Total liabilities169,737162,034
Stockholders' equity:Common stock, $0.00025 par value; 50,000,000 shares authorized; 26,115,126 shares and 25,093,792 shares issued as of September 30, 2026 and December 31, 2025, respectively76
Stockholders' equity:Additional paid-in capital637,299622,325
Stockholders' equity:Accumulated deficit-298,992-275,212
Stockholders' equity:Accumulated other comprehensive income (loss)1,036-523
Stockholders' equity:Total stockholders' equity339,350346,596
Stockholders' equity:Total liabilities and stockholders' equity509,087508,630

Cash Flow

Nine Months Ended September 30, — (Unaudited)(In Thousands) (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
OPERATING ACTIVITIESNet loss-23,780-29,545
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Goodwill and other intangible asset impairments6114,163

Cash Flow

Three Months Ended September 30, — (In Thousands) (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net cash provided by (used in) operating activities (GAAP)4,506-5812,147-15,199
Less: Capital expenditures-2,911-2,839-8,716-10,511
Free cash flow (non-GAAP)1,595-3,420-6,569-25,710

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect,"

"plan," "anticipate," "could," "believe," "estimate," "project," "target," "predict," "intend," "future," "goals," "potential,” "objective," "would" and other similar expressions. Forward-looking statements involve risks and uncertainties, many of which are beyond OrthoPediatrics’ control. Important factors could cause actual results to differ materially from those in the forward-looking statements, including, among others: the risks related to widespread health emergencies, such as respiratory syncytial virus, the impact such pandemics, epidemics and infectious disease outbreaks may have on the demand for our products, and our ability to respond to the related challenges; and the risks, uncertainties and factors set forth under "Risk Factors" in OrthoPediatrics’ Annual Report on Form 10-K filed with the SEC on March 4, 2026, as updated and supplemented by our other SEC reports filed from time to time. Forward-looking statements speak only as of the date they are made. OrthoPediatrics assumes no obligation to update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable securities laws.

Use of Non-GAAP Financial Measures

This press release includes certain non-GAAP financial measures, such as free cash flow, adjusted diluted (loss) earnings per share and Adjusted EBITDA, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). Free cash flow, which we reconcile to "Net cash provided by (used in) operating activities" is cash flow from operations reduced by "Capital expenditures". Adjusted loss per share in this press release represents diluted loss per share on a GAAP basis, excluding intangible asset impairment, fair value adjustment of contingent consideration, restructuring charges, tariffs, European Union Medical Device Regulation fees increase, acquisition-related costs, and minimum purchase commitment costs. We believe that providing the non-GAAP diluted loss per share excluding these expenses, as well as the GAAP measures, assists our investors because such expenses are not reflective of our ongoing operating results. Adjusted EBITDA in this release represents net loss, plus interest expense, net plus other expense (income), net plus income tax charge (benefit), depreciation and amortization, intangible asset impairment, stock-based compensation expense, fair value adjustment of contingent consideration, restructuring charges, tariffs, European Union Medical Device Regulation... (truncated). The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. Free cash flow is a non-GAAP financial measure and has limitations because it does not represent the cash flow available for management's use as it does not reflect capital expenditures which will likely recur in the future. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating these non-GAAP measures, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP free cash flow, diluted loss per share or Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using these adjusted measures on a supplemental basis. The Company’s definition of these measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. The schedules below contain reconciliations of Net cash used in operating activities to Free cash flow (Non-GAAP), GAAP diluted loss per share to non-GAAP diluted loss per share and net loss to non-GAAP Adjusted EBITDA.

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 95 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 75 countries outside the United States. For more information, please visit www.orthopediatrics.com.

Investor Contact

Philip Trip Taylor

Gilmartin Group philip@gilmartinir.com

415-937-5406

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.